留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

小儿血型不合活体肝移植的临床疗效分析

孙超 孟醒初 董冲 王凯 郑卫萍 覃虹 韩潮 杨洋 张复波 曹顺琪 徐敏 高伟

孙超, 孟醒初, 董冲, 等. 小儿血型不合活体肝移植的临床疗效分析[J]. 器官移植, 2020, 11(4): 466-470. doi: 10.3969/j.issn.1674-7445.2020.04.007
引用本文: 孙超, 孟醒初, 董冲, 等. 小儿血型不合活体肝移植的临床疗效分析[J]. 器官移植, 2020, 11(4): 466-470. doi: 10.3969/j.issn.1674-7445.2020.04.007
Sun Chao, Meng Xingchu, Dong Chong, et al. Clinical efficacy analysis of pediatric blood type incompatible living donor liver transplantation[J]. ORGAN TRANSPLANTATION, 2020, 11(4): 466-470. doi: 10.3969/j.issn.1674-7445.2020.04.007
Citation: Sun Chao, Meng Xingchu, Dong Chong, et al. Clinical efficacy analysis of pediatric blood type incompatible living donor liver transplantation[J]. ORGAN TRANSPLANTATION, 2020, 11(4): 466-470. doi: 10.3969/j.issn.1674-7445.2020.04.007

小儿血型不合活体肝移植的临床疗效分析

doi: 10.3969/j.issn.1674-7445.2020.04.007
基金项目: 

天津市卫生行业重点攻关项目 16KG107

天津市器官移植临床医学研究中心项目 15ZXLCSY00070

详细信息
    作者简介:

    孙超,男,1978年生,硕士,主治医师,研究方向为肝移植,Email:sunchaodoc@163.com

    通讯作者:

    高伟,男,1975年生,博士,主任医师,研究方向为肝移植,Email:gaowei_tjfch@163.com

  • 中图分类号: R617, R457.1+1

Clinical efficacy analysis of pediatric blood type incompatible living donor liver transplantation

More Information
  • 摘要:   目的  探讨小儿血型不合活体肝移植的临床疗效。  方法  回顾性分析242例小儿活体肝移植受者的临床资料。根据供、受者血型相合情况分为A组(供、受者血型相同,165例)、B组(供、受者血型相合,42例)、C组(供、受者血型不合,35例)。观察并比较3组受者的术后并发症发生情况、术后供体特异性抗体(DSA)产生情况;分析C组供、受者血型分布及红细胞抗体产生情况;比较3组受者肝移植术后的生存情况。  结果  3组受者并发症发生率比较,差异均无统计学意义(均为P > 0.05)。肝移植术后DSA以人类白细胞抗原(HLA)Ⅱ类抗体为主,多为抗HLA-DR和抗HLA-DQ。C组肝移植受者术后红细胞抗体多为IgM,所有抗体滴度均为≤1:2。3组受者术后生存率差异均无统计学意义(均为P > 0.05)。  结论  小儿血型不合活体肝移植是一种安全有效的治疗方式,可有效扩大肝移植供者来源,挽救患儿生命。

     

  • 图  1  3组肝移植受者的生存曲线

    Figure  1.  Survival curves of liver transplant recipientsin 3 groups

    表  1  3组肝移植受者术后并发症发生情况

    Table  1.   Postoperative complications of liver transplant recipients in 3 groups[n(%)]

    组别 n 细胞性排斥反应 肝动脉血栓 门静脉血栓 门静脉狭窄 肝静脉狭窄 胆漏 胆管狭窄 PTLD
    A组 165 40(24) 0(0) 30(18) 7(4) 5(3) 7(4) 7(4) 6(4)
    B组 42 14(33) 0(0) 0(0) 4(10) 2(5) 4(10) 4(10) 2(5)
    C组 35 7(20) 0(0) 1(3) 3(9) 1(3) 0(0) 2(6) 1(3)
    P 0.2030 0.1962 0.1954 0.2052 0.1977 0.1977 0.2027 0.1966
    注:①PTLD为移植后淋巴组织增生性疾病
    下载: 导出CSV
  • [1] KELLY D, VERKADE HJ, RAJANAYAGAM J, et al. Late graft hepatitis and fibrosis in pediatric liver allograft recipients: current concepts and future developments[J]. Liver Transpl, 2016, 22(11):1593-1602. DOI: 10.1002/lt.24616.
    [2] MYSORE KR, HIMES RW, RANA A, et al. ABO-incompatible deceased donor pediatric liver transplantation: novel titer-based management protocol and outcomes[J]. Pediatr Transplant, 2018, 22(7):e13263. DOI: 10.1111/petr.13263.
    [3] DAHLGREN US, BENNET W. ABO-incompatible liver transplantation - a review of the historical background and results[J]. Int Rev Immunol, 2019, 38(3):118-128. DOI: 10.1080/08830185.2019.1601720.
    [4] HONDA M, SUGAWARA Y, KADOHISA M, et al. Long-term outcomes of ABO-incompatible pediatric living donor liver transplantation[J]. Transplantation, 2018, 102(10):1702-1709. DOI: 10.1097/TP.0000000000002197.
    [5] SUN C, SONG Z, MA N, et al. The management and outcomes of ABO-incompatible pediatric liver transplantation: experience of a single Chinese center[J]. J Pediatr Surg, 2020: S0022-3468(20)30151-2. DOI: 10.1016/j.jpedsurg.2020.01.059.
    [6] KASAHARA M, UMESHITA K, SAKAMOTO S, et al. Living donor liver transplantation for biliary atresia: an analysis of 2 085 cases in the registry of the Japanese Liver Transplantation Society[J]. Am J Transplant, 2018, 18(3):659-668. DOI: 10.1111/ajt.14489.
    [7] CHANG CH, BRYCE CL, SHNEIDER BL, et al. Accuracy of the pediatric end-stage liver disease score in estimating pretransplant mortality among pediatric liver transplant candidates[J]. JAMA Pediatr, 2018, 172(11):1070-1077. DOI: 10.1001/jamapediatrics.2018.2541.
    [8] RAWAL N, YAZIGI N. Pediatric liver transplantation[J]. Pediatr Clin North Am, 2017, 64(3):677-684. DOI: 10.1016/j.pcl.2017.02.003.
    [9] NG VL, MAZARIEGOS GV, KELLY B, et al. Barriers to ideal outcomes after pediatric liver transplantation[J]. Pediatr Transplant, 2019, 23(6):e13537. DOI: 10.1111/petr.13537.
    [10] TOKODAI K, KUMAGAI-BRAESCH M, KARADAGI A, et al. Blood group antigen expression in isolated human liver cells in preparation for implementing clinical ABO-incompatible hepatocyte transplantation[J]. J Clin Exp Hepatol, 2020, 10(2):106-113. DOI: 10.1016/j.jceh.2019.07.001.
    [11] MARKS WH, MAMODE N, MONTGOMERY RA, et al. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial[J]. Am J Transplant, 2019, 19(10):2876-2888. DOI: 10.1111/ajt.15364.
    [12] UMESHITA K, INOMATA Y, FURUKAWA H, et al. Liver transplantation in Japan: registry by the Japanese Liver Transplantation Society[J]. Hepatol Res, 2016, 46(12):1171-1186. DOI: 10.1111/hepr.12676.
    [13] KIVELÄ JM, KOSOLA S, PERÄSAARI J, et al. Donor-specific antibodies after pediatric liver transplantation: a cross-sectional study of 50 patients[J]. Transpl Int, 2016, 29(4):494-505. DOI: 10.1111/tri.12747.
    [14] TOKODAI K, MIYAGI S, NAKANISHI W, et al. Characteristics and predictive value for graft fibrosis of the complement-binding capacity of donor-specific human leukocyte antigen antibodies after pediatric liver transplantation[J]. Pediatr Transplant, 2020, 24(1):e13648. DOI: 10.1111/petr.13648.
    [15] TOKODAI K, MIYAGI S, NAKANISHI C, et al. Effect of recipient age at liver transplantation on prevalence of post-transplant donor-specific HLA antibody[J]. Ann Transplant, 2017, 22:333-337. doi: 10.12659/AOT.903926
    [16] KASAHARA M, KIUCHI T, TAKAKURA K, et al. Postoperative flow cytometry crossmatch in living donor liver transplantation: clinical significance of humoral immunity in acute rejection[J]. Transplantation, 1999, 67(4):568-575. doi: 10.1097/00007890-199902270-00014
    [17] SAVAGE TM, SHONTS BA, LAU S, et al. Deletion of donor-reactive T cell clones after human liver transplant[J]. Am J Transplant, 2020, 20(2):538-545. DOI: 10.1111/ajt.15592.
    [18] PERITO ER, MARTINEZ M, TURMELLE YP, et al. Posttransplant biopsy risk for stable long-term pediatric liver transplant recipients: 451 percutaneous biopsies from two multicenter immunosuppression withdrawal trials[J]. Am J Transplant, 2019, 19(5):1545-1551. DOI: 10.1111/ajt.15255.
    [19] NAKAMURA T, SHIROUZU T, NAKATA K, et al. The role of major histocompatibility complex in organ transplantation- donor specific anti-major histocompatibility complex antibodies analysis goes to the next stage[J]. Int J Mol Sci, 2019, 20(18):E4544. DOI: 10.3390/ijms20184544.
    [20] TOKODAI K, MIYAGI S, NAKANISHI C, et al. Association of post-transplant donor-specific HLA antibody with liver graft fibrosis during long-term follow-up after pediatric liver transplantation[J]. Pediatr Transplant, 2018, 22(3):e13169. DOI: 10.1111/petr.13169.
    [21] FENG S, BUCUVALAS JC, DEMETRIS AJ, et al. Evidence of chronic allograft injury in liver biopsies from long-term pediatric recipients of liver transplants[J]. Gastroenterology, 2018, 155(6):1838-1851. DOI: 10.1053/j.gastro.2018.08.023.
    [22] WOZNIAK LJ, NAINI BV, HICKEY MJ, et al. Acute antibody-mediated rejection in ABO-compatible pediatric liver transplant recipients: case series and review of the literature[J]. Pediatr Transplant, 2017, 21(1). DOI: 10.1111/petr.12791.
    [23] TOKODAI K, MIYAGI S, NAKANISHI C, et al. Impact of the trough level of calcineurin inhibitor on the prevalence of donor-specific human leukocyte antigen antibodies during long-term follow-up after pediatric liver transplantation: antibody strength and complement-binding ability[J]. Transplant Direct, 2017, 3(8):e196. DOI: 10.1097/TXD.0000000000000713.
    [24] 孙超, 李姗霓, 马楠, 等.对小儿肝移植术后早期供体特异性抗体的监测观察[J/CD].实用器官移植电子杂志, 2018, 6(4):300-303. DOI: 10.3969/j.issn.2095-5332. 2018.04.010.

    SUN C, LI SN, MA N, et al. Observation of donor specific antibody in the early period post pediatric liver transplantation[J/CD]. Pract J Organ Transplant (Electr Vers), 2018, 6(4):300-303. DOI: 10.3969/j.issn.2095-5332. 2018.04.010.
    [25] ELISOFON SA, MAGEE JC, NG VL, et al. Society of pediatric liver transplantation: current registry status 2011-2018[J]. Pediatr Transplant, 2020, 24(1):e13605. DOI: 10.1111/petr.13605.
    [26] LEE EC, KIM SH, PARK SJ. Outcomes after liver transplantation in accordance with ABO compatibility: a systematic review and Meta-analysis[J].World J Gastroenterol, 2017, 23(35):6516-6533. DOI: 10.3748/wjg.v23.i35.6516.
    [27] 邢爱丽, 郑加生.经肝动脉化疗栓塞术联合局部热消融治疗大肝癌的效果及影响因素[J].临床肝胆病杂志, 2019, 35(1):98-103.DOI:10.3969/j.issn.1001-5256. 2019.01.018.

    XING AL, ZHENG JS. Clinical effect of transcatheter arterial chemoembolization combined with local thermal ablation in treatment of large hepatocellular carcinoma and related influencing factors[J]. J Clin Hepatol, 2019, 35(1):98-103. DOI: 10.3969/j.issn.1001-5256.2019.01.018.
  • 加载中
图(1) / 表(1)
计量
  • 文章访问数:  37
  • HTML全文浏览量:  20
  • PDF下载量:  15
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-04-21
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2020-07-15

目录

    /

    返回文章
    返回